Literature DB >> 11854209

Mutational analysis of ganglioside GM(1)-binding ability, pentamer formation, and epitopes of cholera toxin B (CTB) subunits and CTB/heat-labile enterotoxin B subunit chimeras.

Michael G Jobling1, Randall K Holmes.   

Abstract

Variants of cholera toxin B subunit (CTB) were made by bisulfite- and oligonucleotide-directed mutagenesis of the ctxB gene. Variants were screened by a radial passive immune hemolysis assay (RPIHA) for loss of binding to sheep erythrocytes (SRBC). Variant CTBs were characterized for the formation of immunoreactive pentamers, the ability to bind ganglioside GM(1) in vitro, and reactivity with a panel of monoclonal anti-CTB antibodies. Substitutions at eight positions (i.e., positions 22, 29, 36, 45, 64, 86, 93, and 100) greatly reduced the yield of immunoreactive CTB. RPIHA-negative substitution variants that formed immunoreactive pentamers were obtained for residues 12, 33, 36, 51, 52 + 54, 91, and 95. Tyrosine-12 was identified as a novel residue important for GM(1) binding since, among all of the novel variants isolated with altered RPIHA phenotypes, only CTB with aspartate substituted for tyrosine at position 12 failed to bind significantly to ganglioside GM(1) in vitro. In contrast, CTB variants with single substitutions for several other residues (Glu-51, Lys-91, and Ala-95) that participate in GM(1) binding, based on the crystal structure of CTB and the oligosaccharide of GM(1), were not appreciably altered in their ability to bind GM(1) in vitro, even though they showed altered RPIHA phenotypes and did not bind to SRBC. Hybrid B genes made by fusing ctxB and the related Escherichia coli heat-labile enterotoxin eltB genes at codon 56 produced CTB variants that had 7 or 12 heat-labile enterotoxin B residue substitutions in the amino or carboxyl halves of the monomer, respectively, each of which which also bound GM(1) as well as wild-type CTB. This collection of variant CTBs in which 47 of the 103 residues were substituted was used to map the epitopes of nine anti-CTB monoclonal antibodies (MAbs). Each MAb had a unique pattern of reactivity with the panel of CTB variants. Although no two of the epitopes recognized by different MAbs were identical, most of the single amino acid substitutions that altered the immunoreactivity of CTB affected more that one epitope. The tertiary structures of the epitopes of these anti-CTB MAbs are highly conformational and may involve structural elements both within and between CTB monomers. Substitution of valine for alanine at positions 10 and 46 had dramatic effects on the immunoreactivity of CTB, affecting epitopes recognized by eight or six MAbs, respectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854209      PMCID: PMC127768          DOI: 10.1128/IAI.70.3.1260-1271.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Erythrocyte receptors for cholera and heat-labile enterotoxins of Escherichia coli.

Authors:  L C Ricci; P S de Siqueira; W M Tamashiro; A F de Castro
Journal:  Res Microbiol       Date:  1989 Jul-Aug       Impact factor: 3.992

2.  Chemical and immunochemical studies on the receptor binding domain of cholera toxin B subunit.

Authors:  D S Ludwig; R K Holmes; G K Schoolnik
Journal:  J Biol Chem       Date:  1985-10-15       Impact factor: 5.157

3.  An improved method to obtain a large number of mutants in a defined region of DNA.

Authors:  R Pine; P C Huang
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

4.  Synthesis of cholera toxin is positively regulated at the transcriptional level by toxR.

Authors:  V L Miller; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

5.  Variation in epitopes of the B subunit of El Tor and classical biotype Vibrio cholerae O1 cholera toxin.

Authors:  M L Tamplin; M K Ahmed; R Jalali; R R Colwell
Journal:  J Gen Microbiol       Date:  1989-05

6.  Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli.

Authors:  T K Sixma; S E Pronk; K H Kalk; E S Wartna; B A van Zanten; B Witholt; W G Hol
Journal:  Nature       Date:  1991-05-30       Impact factor: 49.962

7.  A single amino acid substitution in B subunit of Escherichia coli enterotoxin affects its oligomer formation.

Authors:  T Iida; T Tsuji; T Honda; T Miwatani; S Wakabayashi; K Wada; H Matsubara
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

8.  Epitopes of the cholera family of enterotoxins.

Authors:  R A Finkelstein; M F Burks; A Zupan; W S Dallas; C O Jacob; D S Ludwig
Journal:  Rev Infect Dis       Date:  1987 May-Jun

9.  Characterization of monoclonal antibodies to heat-labile enterotoxin encoded by a plasmid from a clinical isolate of Escherichia coli.

Authors:  B W Belisle; E M Twiddy; R K Holmes
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

10.  Analysis of receptor-binding site in Escherichia coli enterotoxin.

Authors:  T Tsuji; T Honda; T Miwatani; S Wakabayashi; H Matsubara
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

View more
  20 in total

1.  Cholera holotoxin assembly requires a hydrophobic domain at the A-B5 interface: mutational analysis and development of an in vitro assembly system.

Authors:  Juliette K Tinker; Jarrod L Erbe; Wim G J Hol; Randall K Holmes
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

Review 2.  Glycosphingolipid functions.

Authors:  Clifford A Lingwood
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

3.  Sequential One-Pot Multienzyme Chemoenzymatic Synthesis of Glycosphingolipid Glycans.

Authors:  Hai Yu; Yanhong Li; Jie Zeng; Vireak Thon; Dung M Nguyen; Thao Ly; Hui Yu Kuang; Alice Ngo; Xi Chen
Journal:  J Org Chem       Date:  2016-10-24       Impact factor: 4.354

4.  Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.

Authors:  Mari Okayasu; Mai Nakayachi; Chiyomi Hayashida; Junta Ito; Toshio Kaneda; Masaaki Masuhara; Naoto Suda; Takuya Sato; Yoshiyuki Hakeda
Journal:  J Biol Chem       Date:  2012-04-12       Impact factor: 5.157

5.  Streamlined chemoenzymatic total synthesis of prioritized ganglioside cancer antigens.

Authors:  Hai Yu; Abhishek Santra; Yanhong Li; John B McArthur; Tamashree Ghosh; Xiaoxiao Yang; Peng G Wang; Xi Chen
Journal:  Org Biomol Chem       Date:  2018-06-06       Impact factor: 3.876

6.  Binding efficiencies of carbohydrate ligands with different genotypes of cholera toxin B: molecular modeling, dynamics and docking simulation studies.

Authors:  Mobashar Hussain Urf Turabe Fazil; Sunil Kumar; Rohit Farmer; Haushila Prasad Pandey; Durg Vijai Singh
Journal:  J Mol Model       Date:  2011-03-16       Impact factor: 1.810

7.  Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon.

Authors:  K J Baldauf; J M Royal; J C Kouokam; B Haribabu; V R Jala; K Yaddanapudi; K T Hamorsky; G W Dryden; N Matoba
Journal:  Mucosal Immunol       Date:  2016-11-02       Impact factor: 7.313

8.  Expression of toxin co-regulated pilus subunit A (TCPA) of Vibrio cholerae and its immunogenic epitopes fused to cholera toxin B subunit in transgenic tomato (Solanum lycopersicum).

Authors:  Manoj Kumar Sharma; Nirmal Kumar Singh; Dewal Jani; Rama Sisodia; M Thungapathra; J K Gautam; L S Meena; Yogendra Singh; Amit Ghosh; Akhilesh Kumar Tyagi; Arun Kumar Sharma
Journal:  Plant Cell Rep       Date:  2007-10-26       Impact factor: 4.570

Review 9.  Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties.

Authors:  George Hajishengallis; Terry D Connell
Journal:  Vet Immunol Immunopathol       Date:  2012-09-26       Impact factor: 2.046

Review 10.  Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.

Authors:  Terry D Connell
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.